The global chemotherapy induced anemia market was valued at $2.7 billion in 2022, and is projected to reach $5.0 billion by 2032, growing at a CAGR of 6.3% from 2023 to 2032. Chemotherapy-induced anemia (CIA) is a type of anemia that occurs as a side effect of chemotherapy treatment for cancer. Chemotherapy drugs can affect the bone marrow's ability to produce red blood cells, which leads to decrease in the number of red blood cells in the body. Anemia is a condition where the body does not have enough red blood cells to carry oxygen to the tissues. Symptoms of CIA Include fatigue, weakness, shortness of breath, dizziness, and pale skin. Treatment for CIA Includes blood transfusions to replenish red blood cells, erythropoiesis-stimulating agents (ESAs) that help to stimulate the production of red blood cells, and iron supplementation to address functional iron deficiency.
The chemotherapy induced anemia market growth is driven by Increase in prevalence of cancer, rise in demand for targeted therapies, and surge in aging population. The Increasing prevalence of cancer and the associated use of chemotherapy is expected to continue to drive the growth of the chemotherapy-induced anemia market. For instance, in February 2022, the World Health Organization (WHO) estimated that approximately 400,000 children develop cancer every year across the globe. In addition, a study conducted by the National Center for Biotechnology Information (NCBI) in April 2022 estimated the occurrence rate of anemia was about 41.1% in patients suffering from breast cancer. Therefore, the rise in prevalence of cancer drives the growth of the market. In addition, older people are more likely to develop cancer and anemia, which further fuels the demand for drugs to treat chemotherapy induced anemia.
Rise in demand for chemotherapy induced anemia is the key factor driving the growth of chemotherapy induced anemia market. This is attributed to an Increase in appearance of anemia, rise in ageing population, and availability of effective treatment. The aging population is more susceptible to developing cancer, leading to a higher demand for CIA treatment. In addition, development of new and more effective treatments for CIA, Including erythropoiesis-stimulating agents (ESAs) and iron supplementation, has expanded the options available for managing anemia during chemotherapy. Iron supplement is an effective treatment for chemotherapy induced anemia as it has low side-effects as compared with other treatment options.
For instance, in October 2022, the World Health Organization (WHO) estimated that the global population aged 60 years and over is expected to double by 2050 to reach 2.1 billion. Moreover, according to the National Center for Biotechnology Information (NCBI), older adults are more likely to experience anemia as a result of cancer treatment. Furthermore, Increase in awareness about chemotherapy induced anemia among patients and healthcare professionals has led to an Increase in the number of patients seeking treatment for CIA. In addition, rise in government initiatives to improve cancer care and the treatment of chemotherapy-induced anemia (CIA) further propels the market growth. For instance, the federal government announced in May 2020 that it would be investing $150 million over five years in the Canadian Partnership against Cancer, with a focus on improving access to cancer care and support for patients. Thus, a rise in government initiatives further boosts the market growth.
However, the high cost of chemotherapy induced anemia therapies and side effects associated with the ESAs limit the adoption of these treatments, which negatively impacts the market growth. For instance, the cost of blood transfusion ranges from $200 to $300 per pint of blood. Thus, the high cost of blood transfusion and other drugs negatively impact market growth. On the other hand, development of novel therapies for the treatment of chemotherapy induced anemia with lower side effects and Increase in R&D activities for developing advanced therapies are expected to create immense opportunities for the growth of chemotherapy induced anemia market during the forecast period. The chemotherapy induced anemia market is segmented on the basis of grade, treatment, end user, and region. On the basis of grade, the market is classified into grade 1, grade 2, and grade 3&4. As per treatment, the market is segmented into blood transfusion, erythropoietin-stimulating agents, and iron & other supplements.
On the basis of end user, the market is segmented into hospitals, cancer centers, and others. The other segment Includes cancer research centers, cancer rehabilitation centers, and home use. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the global chemotherapy induced anemia market are Pfizer Inc., Dr. Reddy’s Laboratories Ltd., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Amgen Inc., Novartis AG, 3SBio Group, Bristol-Myers Squibb Company, FibroGen, Inc., and Astella Pharma
The chemotherapy induced anemia market growth is driven by Increase in prevalence of cancer, rise in demand for targeted therapies, and surge in aging population. The Increasing prevalence of cancer and the associated use of chemotherapy is expected to continue to drive the growth of the chemotherapy-induced anemia market. For instance, in February 2022, the World Health Organization (WHO) estimated that approximately 400,000 children develop cancer every year across the globe. In addition, a study conducted by the National Center for Biotechnology Information (NCBI) in April 2022 estimated the occurrence rate of anemia was about 41.1% in patients suffering from breast cancer. Therefore, the rise in prevalence of cancer drives the growth of the market. In addition, older people are more likely to develop cancer and anemia, which further fuels the demand for drugs to treat chemotherapy induced anemia.
Rise in demand for chemotherapy induced anemia is the key factor driving the growth of chemotherapy induced anemia market. This is attributed to an Increase in appearance of anemia, rise in ageing population, and availability of effective treatment. The aging population is more susceptible to developing cancer, leading to a higher demand for CIA treatment. In addition, development of new and more effective treatments for CIA, Including erythropoiesis-stimulating agents (ESAs) and iron supplementation, has expanded the options available for managing anemia during chemotherapy. Iron supplement is an effective treatment for chemotherapy induced anemia as it has low side-effects as compared with other treatment options.
For instance, in October 2022, the World Health Organization (WHO) estimated that the global population aged 60 years and over is expected to double by 2050 to reach 2.1 billion. Moreover, according to the National Center for Biotechnology Information (NCBI), older adults are more likely to experience anemia as a result of cancer treatment. Furthermore, Increase in awareness about chemotherapy induced anemia among patients and healthcare professionals has led to an Increase in the number of patients seeking treatment for CIA. In addition, rise in government initiatives to improve cancer care and the treatment of chemotherapy-induced anemia (CIA) further propels the market growth. For instance, the federal government announced in May 2020 that it would be investing $150 million over five years in the Canadian Partnership against Cancer, with a focus on improving access to cancer care and support for patients. Thus, a rise in government initiatives further boosts the market growth.
However, the high cost of chemotherapy induced anemia therapies and side effects associated with the ESAs limit the adoption of these treatments, which negatively impacts the market growth. For instance, the cost of blood transfusion ranges from $200 to $300 per pint of blood. Thus, the high cost of blood transfusion and other drugs negatively impact market growth. On the other hand, development of novel therapies for the treatment of chemotherapy induced anemia with lower side effects and Increase in R&D activities for developing advanced therapies are expected to create immense opportunities for the growth of chemotherapy induced anemia market during the forecast period. The chemotherapy induced anemia market is segmented on the basis of grade, treatment, end user, and region. On the basis of grade, the market is classified into grade 1, grade 2, and grade 3&4. As per treatment, the market is segmented into blood transfusion, erythropoietin-stimulating agents, and iron & other supplements.
On the basis of end user, the market is segmented into hospitals, cancer centers, and others. The other segment Includes cancer research centers, cancer rehabilitation centers, and home use. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the global chemotherapy induced anemia market are Pfizer Inc., Dr. Reddy’s Laboratories Ltd., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Amgen Inc., Novartis AG, 3SBio Group, Bristol-Myers Squibb Company, FibroGen, Inc., and Astella Pharma
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the chemotherapy induced anemia market analysis from 2022 to 2032 to identify the prevailing chemotherapy induced anemia market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the chemotherapy induced anemia market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report Includes the analysis of the regional as well as global chemotherapy induced anemia market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Grade
- Grade 1
- Grade 2
- Grade 3 and 4
By Treatment
- Blood transfusion
- Erythropoiesis stimulating agents
- Type
- Long Acting Erythropoietin stimulating agents
- Short Acting Erythropoietin stimulating agents
- Iron and others supplementation
By End User
- Hospitals
- Cancer center
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Dr. Reddy’s Laboratories Ltd.
- 3SBio Group
- Johnson & Johnson
- FibroGen, Inc.
- Novartis AG
- Pfizer Inc.
- Amgen Inc.
- Astellas Pharma Inc.
- F. Hoffmann-La Roche Ltd.
- Bristol-Myers Squibb Company
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: CHEMOTHERAPY INDUCED ANEMIA MARKET, BY GRADE
CHAPTER 5: CHEMOTHERAPY INDUCED ANEMIA MARKET, BY TREATMENT
CHAPTER 6: CHEMOTHERAPY INDUCED ANEMIA MARKET, BY END USER
CHAPTER 7: CHEMOTHERAPY INDUCED ANEMIA MARKET, BY REGION
CHAPTER 8: COMPETITIVE LANDSCAPE
CHAPTER 9: COMPANY PROFILES
List of Tables
List of Figures
Executive Summary
According to a new report, titled, 'Chemotherapy Induced Anemia Market,' The chemotherapy induced anemia market was valued at $2.7 billion in 2022, and is estimated to reach $5 billion by 2032, growing at a CAGR of 6.3% from 2023 to 2032. Chemotherapy-induced anemia (CIA) is a specific type of anemia that occurs as a side effect of chemotherapy treatment for cancer. Chemotherapy drugs can disrupt the normal functioning of the bone marrow, which is responsible for producing red blood cells. As a result, there is a decrease in the number of red blood cells circulating in the body, leading to anemia. CIA can cause various symptoms such as fatigue, weakness, shortness of breath, dizziness, and pale skin. These symptoms can significantly impact the quality of life and overall well-being of cancer patients undergoing chemotherapy. The treatment of CIA includes blood transfusion, erythropoiesis-stimulating agents (ESAs), and iron & other Iron supplementation.Key factors driving the growth of the chemotherapy induced anemia market include rise in number of individuals undergoing chemotherapy, increase in prevalence of cancer, and surge in appearance of chemotherapy induced anemia. The rise in incidence of cancer contributes to the higher number of patients receiving chemotherapy, subsequently leading to an increased prevalence of chemotherapy-induced anemia. For instance, in June 2020, FibroGen, Inc., a biotechnology research company, estimated that approximately 1.3 million patients in the U.S. undergo chemotherapy annually. Out of these patients, about 30% to 90%, develop anemia. Furthermore, Rise in demand for chemotherapy induced anemia treatment also boost the market growth. The aging population is more susceptible to developing cancer, and as the global population ages, the incidence of cancer in this demographic increases as well. Older individuals are more likely to require chemotherapy, this has led to rise in demand for CIA treatment.
In addition, the development of new and more effective treatments for CIA, such as erythropoiesis-stimulating agents (ESAs) and iron supplements, has expanded the range of options available for managing anemia during chemotherapy. ESAs helps to stimulate the production of red blood cells. Thus, availability and effectiveness of these treatments have contributed to an increased demand for CIA treatment, which, in turn contribute towards the market growth. Rise in awareness among healthcare professionals and patients about the significance of managing anemia as an integral part of cancer treatment also propels the growth of the chemotherapy-induced anemia (CIA) market.
For instance, according to the Cancer India Organization, the incidence rate of cancer is high at ages 50-64 years in Indians. In addition, as per the same source in 2022, about 1 in 29 women is expected to develop cancer during her lifetime. Moreover, the rise in demand for advanced healthcare services and many countries in this region has increased their investment in healthcare systems.
Moreover, increase in appearance of anemia in cancer patients and development of novel therapies are expected to create lucrative opportunities for the market growth during the forecast period. For instance, ESAs used to treat chemotherapy induced anemia are associated with various side effects, such as increased risk of blood clots, stroke, and even death. As a result, there is a growing demand for new and innovative therapies for CIA that offer improved safety profiles compared to ESAs. The development of novel therapies like Roxadustat has high potential to treat chemotherapy induced anemia and has minimum side effects as compared to ESAs.
The chemotherapy induced anemia market is segmented on the basis of grade, treatment, end user, and region. On the basis of grade, the market is classified into grade 1, grade 2, and grade 3&4. As per treatment, the market is segmented into blood transfusion, erythropoietin-stimulating agents, and iron & other supplements. On the basis of end user the market is segmented into hospital, cancer centers, and others. Others segment include cancer research center, cancer rehabilitation center, and home use. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
The key players profiled in the study include Pfizer Inc., Dr. Reddy’s Laboratories Ltd., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Amgen Inc., Novartis AG, 3SBio Group, Bristol-Myers Squibb Company, FibroGen, Inc., and Astella Pharma.
Key Market Insights
- By grade, the grade 1 segment was the highest revenue contributor to the market in 2022 and is estimated to reach $3,612.0 million by 2032.
- On the basis of treatment, the erythropoietin stimulating agents segment dominated the global market and it is expected to register highest CAGR during the forecast period.
- By end user, the hospital segment dominated the global market in 2022.
- Based on region, North America garnered the largest revenue share in 2022. However Asia-Pacific is anticipated to grow at the highest CAGR of 7.5% during the forecast period.
Companies Mentioned
- Dr. Reddy’s Laboratories Ltd.
- 3SBio Group
- Johnson & Johnson
- FibroGen, Inc.
- Novartis AG
- Pfizer Inc.
- Amgen Inc.
- Astellas Pharma Inc.
- F. Hoffmann-La Roche Ltd.
- Bristol-Myers Squibb Company
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 249 |
| Published | May 2023 |
| Forecast Period | 2022 - 2032 |
| Estimated Market Value ( USD | $ 2.7 billion |
| Forecasted Market Value ( USD | $ 5 billion |
| Compound Annual Growth Rate | 6.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
